Back to results
US 2026/0031230 A1Published application
Methods of identifying pancreatic cancer
AssigneePrognomIQ, Inc.
InventorsPhilip MA, Bruce WILCOX, Chinmay BELTHANGADY, John BLUME, Manway LIU, Ehdieh KHALEDIAN, Preston B. WILLIAMS
Life of this patent
Estimating the term…
Abstract
Described herein are methods for identifying a biological state such as pancreatic cancer in a subject. For example, a method may include obtaining protein data, transcriptomic data, genomic data, lipidomic data, or metabolomic data of a subject and identifying a likelihood of the subject having pancreatic cancer. The disclosure includes methods of making and using classifiers.
Claims21
-157. (canceled)
A pancreatic cancer evaluation method, the method comprising:
- (a) obtaining a data set comprising biomarker measurements of a biofluid sample from a subject, wherein the biomarker measurements correspond to biomarkers comprising AACT, A1AT, A2GL, AMPN, LBP, ICAM1, PIGR, CO5, S10A8, CO2, CO9, ITIH3, RET4, FCG3A, TETN, CRP, NOE1, F13B, APOA2, or APOA1, or a combination thereof,
- (b) applying a classifier to the data set to qualitatively or quantitatively determine a pancreatic cancer state in the subject, wherein the pancreatic cancer state when determined qualitatively comprises a positive result indicative of the pancreatic cancer in the subject or a negative result indicative of a lack of the pancreatic cancer in the subject, and wherein the pancreatic cancer state when determined quantitatively comprises a degree of risk that the subject has the pancreatic cancer;
- and
- (c) administering a pancreatic cancer treatment to the subject when the pancreatic cancer state is the positive result or when the degree of risk that the subject has the pancreatic cancer is higher than normal;
- or
- (d) observing or treating the subject without administering the pancreatic cancer treatment to the subject when the pancreatic cancer state is the negative result or when the degree of risk is at or below a normal risk that the subject has the pancreatic cancer.
3 more elements
A system, comprising:
- one or more processors;
- and
- one or more memories storing machine-executable code that, when executed, cause the one or more processors to:
- receive a data set comprising biomarker measurements of a biofluid sample from a subject, wherein the biomarker measurements correspond to biomarkers comprising AACT, A1AT, A2GL, AMPN, LBP, ICAM1, PIGR, CO5, S10A8, CO2, CO9, ITIH3, RET4, FCG3A, TETN, CRP, NOE1, F13B, APOA2, or APOA1, or a combination thereof;
- apply a classifier to the data set to qualitatively or quantitatively determine a pancreatic cancer state in the subject, wherein the pancreatic cancer state when determined qualitatively comprises a positive result indicative of the pancreatic cancer in the subject or negative result indicative of a lack of the pancreatic cancer in the subject, and wherein the pancreatic cancer state when determined quantitatively comprises a degree of risk that the subject has the pancreatic cancer;
- and
- provide information to aid in a treatment of the subject, wherein the treatment comprises:
- administering a pancreatic cancer treatment to the subject when the pancreatic cancer state is the positive result or when the degree of risk that the subject has the pancreatic cancer is higher than normal;
- or
- observing the subject or treating the subject without administering the pancreatic cancer treatment to the subject when the pancreatic cancer state is the negative result or when the degree of risk is at or below a normal risk that the subject has the pancreatic cancer.
7 more elements
Dependencies are inferred from the claim text.